Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06312176
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-03-07
Brief Title:
A Study of Sacituzumab Tirumotecan MK-2870 as a Single Agent and in Combination With Pembrolizumab MK-3475 Versus Treatment of Physicians Choice in Participants With HRHER2- Unresectable Locally Advanced or Metastatic Breast Cancer MK-2870-010
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-14
Start Date Type:
ACTUAL
Primary Completion Date:
2027-07-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-04-12
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-07
First Submit QC Date:
March 7 2024
Study First Post Date:
2024-03-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-17
Last Update Post Date:
2024-07-15
Last Update Post Date Type:
ESTIMATED